Asia Green Biotechnology

Asia Green Biotechnology FCF Conversion

Delisted·Sep 23, 2026

The FCF Conversion Rate (FCF/EBITDA) of Asia Green Biotechnology (ASIA.CN) as of Nov 15, 2026 is 16.32 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 65.49 % — a change of -75.08% (lower).

FCF Conversion

16.32 %

YoY

-75.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Asia Green Biotechnology is 2023 16.32 % . FCF Conversion Rate (FCF/EBITDA) of Asia Green Biotechnology was 2022 65.49 % . It decreases by -75.08% lower compared to the previous year.

The Asia Green Biotechnology FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
8.83 CAD
Jan 1, 2019
87.42 CAD
Jan 1, 2020
115.91 CAD
Jan 1, 2021
88.44 CAD
Jan 1, 2022
65.49 CAD
Jan 1, 2023
16.32 CAD
The Asia Green Biotechnology FCF Conversion history
YEARFCF ConversionYoY
16.32 %-75.08%
65.49 %-25.95%
88.44 %-23.70%
115.91 %+32.59%
87.42 %+889.91%
8.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Asia Green Biotechnology Stock analysis

What does Asia Green Biotechnology do? Asia Green Biotechnology Corp develops and supplies proprietary organic hybridization technology for agri-technology applications. The company partners with InPlanta Biotechnology Inc. for hemp cultivation under a license agreement, and collaborates with Swysh Inc. and Pathway Rx Corp for cannabinoid extract development. Revenue is generated through the supply of technology and related products, with operations expanding in Cambodia and Thailand through R&D programs. The firm focuses on commercial hemp and cannabinoid product development under licensed agreements. The company's primary market segments include agricultural technology providers and medicinal cannabinoid extract buyers. InPlanta Biotechnology Inc. licenses hemp cultivation, while Swysh Inc. and Pathway Rx Corp. license cannabinoid extract development. Asia Green Biotechnology Corp. supplies technology and manages the commercialization of these products derived from its organic hybridization technology. Asia Green Biotechnology Corp. operates under license agreements with InPlanta Biotechnology Inc., Swysh Inc., and Pathway Rx Corp. to develop and supply hemp and cannabinoid products. The company's revenue streams come from technology supply and product commercialization under these agreements, with R&D programs in Cambodia and Thailand supporting future market expansion. Asia Green Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Asia Green Biotechnology stock

FCF Conversion Rate (FCF/EBITDA) of Asia Green Biotechnology is 16.32 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Asia Green Biotechnology changed from 65.49 % to 16.32 %, representing a -75.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Asia Green Biotechnology since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Asia Green Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Asia Green Biotechnology

All Key Metrics — Asia Green Biotechnology